A study using brain imaging and biomarker data identified three distinct patterns of cognitive decline in people with preclinical Alzheimer's disease.
Key Details
- 1Researchers analyzed 6-year data from the A4 and LEARN studies, involving people with preclinical Alzheimer's.
- 2Three cognitive trajectories were identified: stable, slow decline, and fast decline; 70% of participants remained stable.
- 3Higher baseline levels of phosphorylated tau (P-tau217) and brain scan tau markers, as well as smaller hippocampal volumes, predicted greater cognitive decline.
- 4Biomarker models could predict stable vs. declining status with about 70% accuracy.
- 5Findings suggest many clinical trial participants do not decline, complicating drug effect measurement.
Why It Matters
The study advances understanding of heterogeneity in Alzheimer's progression and highlights the potential for imaging biomarkers (e.g., PET, MRI) to inform prognosis and participant selection in clinical trials. Improved prediction via imaging and AI could optimize trial design and enable more personalized care in neurodegenerative disease.
Source
EurekAlert
Related News
•EurekAlert
Review Finds AI Model Architecture Key for Brain Tumor MRI Segmentation
A systematic review highlights that AI model architecture, more than data or imaging specifics, drives improved tumor segmentation in brain MRI scans.
•EurekAlert
Mount Sinai to Showcase AI Innovations in Lung and Sleep Imaging at ATS 2026
Mount Sinai experts will present new research on AI and imaging for lung nodules, sleep apnea, and cardiovascular risk at the ATS 2026 Conference.
•EurekAlert
AI Doctor Avatars Boost Cancer Patient Understanding Before Radiology Consults
Meeting an AI avatar doctor before consultations helps cancer patients understand treatment better and reduces stress.